Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07737756 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia

Study acronym: SMA-REAL
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Aug 20, 2026 to Aug 25, 2026 · Study sites: 0 to 1 · Primary and study completion dates: Nov 20, 2026 to Nov 25, 2026 · 2 more Show 5 more changesShow less
    • Start date changed from estimate of Aug 20, 2026 to Aug 25, 2026
    • Study sites: 0 to 1
    • Primary and study completion dates: Nov 20, 2026 to Nov 25, 2026
    • Secondary endpoints: details revised at 7 of 10 entries
    • Eligibility criteria expanded, about 4 words
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this retrospective medical chart review is to describe the clinical outcomes, clinical characteristics, and demographics of patients with spinal muscular atrophy (SMA) type 1 treated with onasemnogene abeparvovec (OA) at a single clinical center in Saudi Arabia. The study will use secondary data collected from the electronic medical records of SMA type 1 patients.
Trial Details
NCT Number NCT07737756
Lead Sponsor Novartis Pharmaceuticals
Conditions Spinal Muscular Atrophy
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov